AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:13 2025-01-16 am EST			5-day change	1st Jan Change
10,844.00 ^GBX	+1.84%		+0.84%	+3.59%

Jan. 15	Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca	MT
Jan. 15	ASTRAZENECA : JP Morgan reaffirms its Buy rating	ZD

Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List

November 29, 2024 at 08:10 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about AstraZeneca PLC

Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca	Jan. 15	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Jan. 15	ZD
Stockholm Bullets - Millicom rises on new dividend policy	Jan. 15	FW
Hutchmed lung cancer treatment Orpathys approved in China	Jan. 14	AN
Two experts give tips on dividend portfolios	Jan. 14	FW
Swedish stocks in North America - Autoliv up 1.1 percent	Jan. 14	FW
Hutchmed Announces NMPA Full Approval for Orpathys (Savolitinib) in China for Patients with Locally Advanced or Metastatic Met Exon 14 NSCLC	Jan. 13	CI
Philips CEO sees subdued China sales this year	Jan. 13	RE
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	Jan. 13
Synthego Signs Strategic Agreement with Astrazeneca to License CRISPR Gene Editing Enzyme	Jan. 13	CI
Astrazeneca Receives Priority Review for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer	Jan. 13	MT
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	Jan. 13	ZD
Deutsche Bank cuts Direct Line to 'hold'	Jan. 13	AN
AstraZeneca and Daiichi Sankyo cheer priority US review of cancer drug	Jan. 13	AN
AstraZeneca: priority review in the USA for Dato-DXd	Jan. 13	CF
Handelsbanken makes several changes to its sector favorites	Jan. 13	FW
AstraZeneca, Daiichi Sankyo Get Priority Review Designation from US FDA for Lung Cancer Treatment	Jan. 13	MT
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	Jan. 13	CI
AstraZeneca PLC Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025	Jan. 12
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Jan. 10	MT
Annexon, Inc. Appoints William ?BJ? Jones to Its Board of Directors	Jan. 10	CI
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth	Jan. 10	MT
AstraZeneca breast cancer drug Lynparza given green light for NHS use	Jan. 09	AN
Di adds Sampo to low-risk portfolio, SCA removed	Jan. 09	FW
Johnson & Johnson Reports 'Statistically Significant' Data From Trial of Rybrevant, Lazcluze Combination to Treat Lung Cancer	Jan. 07	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company